Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL355504 | 0.86 | ALDH1A1 (0.58) | SMN1; SMN2ALDH1A1GPR119L3MBTL1USP30 | |
| SCHEMBL30479010 | 0.86 | ALDH1A1 (0.58) | SMN1; SMN2ALDH1A1GPR119L3MBTL1USP30 | |
| SCHEMBL21786071 | 0.86 | CNR1 (0.44) | SMN1; SMN2ALDH1A1CNR1GPR119L3MBTL1 | |
| SCHEMBL21786123 | 0.83 | MAPT (0.53) | ALDH1A1LMNAMAPTDPP4 | |
| SCHEMBL27162423 | 0.82 | GPR119 (0.46) | SMN1; SMN2ALDH1A1CNR1GPR119L3MBTL1 | |
| SCHEMBL4939884 | 0.81 | ALDH1A1 (0.68) | SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL31640106 | 0.80 | DPP4 (0.44) | CNR1GPR119DPP4 | |
| SCHEMBL4516970 | 0.80 | GPR119 (0.61) | GPR119 | |
| SCHEMBL27162301 | 0.80 | ALDH1A1 (0.53) | ALDH1A1GPR119LMNAMAPTDPP4 | |
| SCHEMBL24215767 | 0.79 | GPR119 (0.47) | SMN1; SMN2ALDH1A1GPR119L3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023129506-A1 | POTENT AND SELECTIVE SMARCA2 DEGRADING CHIMERIC MOLECULES AS CANCER THERAPEUTICS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-07-06 | — | — | WO | disclosed |